<DOC>
	<DOCNO>NCT00318903</DOCNO>
	<brief_summary>There need effective therapy patient follow surgery esophageal carcinoma . Docetaxel Irinotecan , independent , demonstrated activity disease . There interest combination two active agent plus radiotherapy .</brief_summary>
	<brief_title>Irinotecan Taxotere With Radiotherapy Preoperative Treatment Resectable Esophageal Cancer</brief_title>
	<detailed_description>The high rate local distant failure follow surgery esophageal carcinoma necessitates effective therapy patient . The merit neoadjuvant chemotherapy early management micrometastatic disease radiosensitization . A longstanding regimen , 5-FU Cisplatin , fail produce substantial survival benefit , approach result pathologic complete response prior surgical eradication diseased organ . This raise question organ preservation patient . Docetaxel Irinotecan demonstrate independent activity disease radiosensitizers . In study , Docetaxel Irinotecan give together weekly 3 consecutive week attempt decrease recurrence systemic disease , follow give agent independently radiation therapy decrease local relapse rate independently measure toxicity radiation . Following completion chemoradiotherapy , patient undergo resection evaluate pathologic response rate .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histological confirmation adenocarcinoma/squamous cell carcinoma esophagus . Patients consider resection candidate , Clinical Stages II IV ( For GE junction tumor 50 % tumor must within esophagus ) Age 19 year Male female gender ( pregnant lactating ) . If subject fertile , use medically acceptable contraception require , woman reproductive potential shall negative pregnancy test . Patient able understand offer sign write informed consent prior study entry . No prior receipt surgery , chemotherapy , radiotherapy immunotherapy . Patients must demonstrate ECOG P.S . ≤ 1 Minimum life expectancy 12 week End Organ function must adequate meeting criterion baseline : WBC 3000/mm3 , ANC 1500/mm3 , Hgb 9.0 g/dL , PLT 100,000mm3 Normal serum creatinine ( 1.5 mg/dL ) Total Bilirubin ULN , Transaminases ( SGOT and/or SGPT ) may 1.5 x institutional upper limit normal ( ULN ) alkaline phosphatase &lt; ULN , alkaline phosphatase may 4 x ULN transaminases &lt; ULN . PT/PTT upper limit normal ( patient may 1mg Coumadin line patency ) Peripheral neuropathy must &lt; Grade 1 Diagnosis active , invasive ( treat past 5 year ) concomitant malignancy except nonmelanotic skin cancer Patients must fully recover reversible side effect prior intervention Presence underlying disease state associate impairment performance status New York Heart Association Class IV congestive heart failure Limited mental capacity language skill extent simple instruction follow information regard adverse event provide History noncompliance prescribe medical care . Patients history severe hypersensitivity reaction Taxotere® drug formulate polysorbate 80 must exclude .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Chemotherapy cancer esophagus</keyword>
	<keyword>Radiotherapy cancer esophagus</keyword>
	<keyword>Surgery cancer esophagus</keyword>
	<keyword>Chemotherapy , radiotherapy , surgery esophageal cancer</keyword>
</DOC>